Eric Sullivan - 15 Dec 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Role
Chief Financial Officer
Signature
/s/ Margaret Siegel as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Dec 2022
Net transactions value
$0
Form type
4
Filing time
19 Dec 2022, 16:29:17 UTC
Previous filing
27 Jun 2022
Next filing
01 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Stock Option (Right to Buy) Award $0 +40,820 $0.000000 40,820 15 Dec 2022 Common Stock 40,820 $0.9700 Direct F1
transaction TCRR Restricted Stock Unit (Right to Buy) Award $0 +6,804 $0.000000 6,804 15 Dec 2022 Common Stock 6,804 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on the one-year anniversary of the date of grant, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F2 Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
F3 The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter.